Riboxin Reneval, 200 mg 50 pcs

Pharmacotherapeutic group: metabolic agent.

The ATX code: C01EB

Pharmacological properties

Pharmacodynamics

Inosine is a derivative (nucleoside) of purine, precursor of adenosine triphosphate (ATP). It belongs to the group of drugs stimulating metabolic processes. It has antihypoxic and antiarrhythmic effects. It increases myocardial energy balance, improves coronary circulation, and prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and promotes metabolism in hypoxia and in the absence of ATP.

It also activates pyruvic acid metabolism, which is necessary for normal tissue respiration, and helps activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides and enhances the activity of some Krebs cycle enzymes. By penetrating into cells, it has a positive effect on metabolic processes in the myocardium: it increases the force of heart contractions and promotes fuller myocardial relaxation in diastole, resulting in an increase in stroke volume. The mechanism of antiarrhythmic action is not fully understood.

Limits platelet aggregation, activates tissue regeneration (especially myocardium and gastrointestinal mucosa).

Pharmacokinetics

It is well absorbed in the gastrointestinal tract. It is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted by the kidneys.

Indications

Prescribed to adults in the treatment of ischemic heart disease after myocardial infarction, heart rhythm disorders caused by the use of cardiac glycosides.

In the treatment of hepatitis, cirrhosis, fatty liver caused by alcohol or medications, with ucoproporphyria.

Active ingredient

Inosin

Composition

Active ingredient:

Inosine – 200,0000 mg;

Excipients: potato starch, povidone K 30, stearic acid, sucrose (sugar); composition of coating: OPADRY® II COMPLETE FILM COATING SYSTEM 85F32554 YELLOW [polyvinyl alcohol, titanium dioxide, macrogol (polyethylene glycol), talc, quinoline yellow aluminum varnish (E104), iron oxide yellow dye (E172)]

How to take, the dosage

Orally before meals. If the drug is taken orally the daily dose is 0.6-2.4 g.

During the first days of treatment the daily dose is 0.6-0.8 g (0.2 g 3-4 times a day).

In case of good tolerance the daily dose is increased (on the 2nd or 3rd day up to 1.2 g (0.4 g 3 times a day), if necessary – up to 2.4 g a day.

The course duration is from 4 weeks to 1,5-3 months.

In case of urocoproporphyria the daily dose is 0,8 g (0,2 g 4 times a day).

The preparation is taken daily during 1-3 months.

Interaction

When concomitant use with cardiac glycosides, the drug may prevent arrhythmias and increase the positive inotropic effect. Immunosuppressants (immunoglobulin antithymocyte, cyclosporine, gamma-D-glutamyl-D-tryptophan and others) reduce the effect of inosine.

Special Instructions

Riboxin is not used for emergency correction of cardiac abnormalities. In renal failure, the drug may be used only if, in the opinion of the physician, the expected positive effect exceeds the possible risk of use. During long-term treatment, it is desirable to monitor the concentration of uric acid in blood and urine. In case of skin itching and hyperemia, treatment with the drug should be canceled.

Influence on driving and operating machinery

It does not affect the ability to drive vehicles and operate mechanisms requiring increased concentration.

Synopsis

Round biconvex film-coated tablets, light yellow, yellowish or greenish-yellow in color. On cross section the core is white or almost white. Roughness of the surface is allowed.

Contraindications

Hypersensitivity to inosine or other ingredients of the drug;

• podagra;
• hyperuricemia;
• fructose intolerance;
• sugarase/isomaltase deficiency;
• glucose-galactose malabsorption syndrome;
• pregnancy;
• breastfeeding period;
• age under 18 years (effectiveness and safety not established).

With caution

Renal insufficiency.

Side effects

Allergic reactions: urticaria, skin itching, skin hyperemia (the drug should be canceled).

Laboratory indicators: increased uric acid concentration in the blood.

Other: exacerbation of the course of gout (with prolonged use). It is important to report the development of adverse reactions in order to ensure continuous monitoring of the benefit-risk ratio of the drug.

If any of the side effects specified in the instructions worsen, or if you notice any other side effects not specified in the instructions, inform your doctor.

Medical professionals report any adverse reactions of the drug through the national systems for reporting adverse reactions.

Overdose

No cases of overdose have been reported to date.

Pregnancy use

The drug is contraindicated during pregnancy and during breast-feeding. There are no data on penetration of inosin into breast milk, therefore, if it is necessary to use the drug during breast-feeding, breast-feeding should be stopped.

Similarities

Riboxin Bufus, Riboxin-Solofarm